- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07945067
Stigma Reduction Intervention for MSM and Healthcare Providers
Adapting an Intervention to Reduce Stigma Among MSM and Healthcare Providers in Vietnam
This study describes only the Aim 2 clinical trial component of the NIH-funded project "Adapting an Intervention to Reduce Stigma among MSM and Healthcare Providers in Vietnam". The purpose of this pilot randomized waitlist-controlled trial (N=180) is to evaluate the preliminary efficacy of DONGHANH, a stigma-reduction intervention for men who have sex with men and healthcare providers in Vietnam. The study will provide preliminary data on the intervention's potential impact to inform the design of a larger future trial evaluating its effects on HIV prevention and care outcomes in Vietnam and in other countries with collectivist cultures.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a pilot randomized waitlist-controlled trial of DONGHANH, a stigma-reduction intervention for men who have sex with men (MSM) and healthcare providers (HCP) in Vietnam. Participants are randomized 1:1 to receive DONGHANH immediately or to a waitlist control. Waitlist participants receive the same DONGHANH workshops after the 3-month assessment. Assessments occur at baseline and 3 months for all participants. Participants in the immediate intervention arm complete an additional assessment at 6 months. Efficacy outcomes are analyzed using generalized linear mixed models or generalized estimating equations, with the intervention-by-time interaction as the primary test of effect.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Toan Ha, MD, DrPH
- Phone Number: 412-383-4576
- Email: toh33@pitt.edu
Study Locations
-
-
-
Hanoi, Vietnam
- Institute of Social and Medical Studies
-
Contact:
- Nam T Nguyen, MD, DrPH
- Phone Number: +84-02435558288
- Email: ntnam@isms.org.vn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
MSM:
- Age 18 years or older
- Cisgender male
- HIV-positive, HIV-negative, or unknown HIV status
- Self-reported history of condomless sex
- Able to provide written informed consent
Healthcare providers:
- Age 18 years or older
- Works in an HIV outpatient clinic or community-based organization clinic in Hanoi
- Able to provide informed consent
Exclusion Criteria:
- Unable to provide informed consent
- Unable to read and understand Vietnamese
- Currently enrolled in another HIV intervention study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: DONGHANH Intervention
DONGHANH is a stigma-reduction intervention for men who have sex with men (MSM) and healthcare provider (HCP) in Vietnam. The intervention is delivered through five workshops attended jointly by MSM and HCP participants. Each workshop lasts approximately 1.5 days and consists of 10 modules. The modules use presentations, group discussions, and interactive exercises to build understanding of HIV-related and sexuality-related stigma; facilitate the sharing of personal experiences of stigma among MSM and HCP participants; explore the health effects of stigma; and develop strengths and strategies for coping with and reducing stigma. |
DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies. |
|
Experimental: Waitlist control group
Participants in this arm receive no intervention for the first 3 months after randomization. During this period, study staff contact them every 2 weeks to maintain retention. These contacts do not include any intervention content. After the 3-month assessment, participants receive the same DONGHANH workshops Assessments occur at baseline, 3 months and 6 months |
DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of the intervention
Time Frame: 3 months
|
Feasibility of the intervention will be assessed with the feasibility of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater perceived feasibility. Results will be reported separately for among MSM and healthcare providers. |
3 months
|
|
Acceptability of of the intervention
Time Frame: 3 months
|
Acceptability of the intervention will be assessed with the acceptability of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater acceptability. Results will be reported separately for MSM and healthcare providers. |
3 months
|
|
Appropriateness of the intervention
Time Frame: 3 months
|
Appropriateness of the intervention will be assessed using the intervention appropriateness measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The overall score is calculated as the mean of the four items, ranging from 1 to 5. Higher scores indicate greater perceived appropriateness. Results will be reported separately for MSM and healthcare providers. |
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in stigma
Time Frame: Baseline, 3 months, and 6 months
|
Change in stigma will be measured using the homosexuality-related stigma scale (Vietnamese version), a self-report measure of stigma among MSM. The scale has three subscales: enacted stigma (7 items, rated 1 [never] to 4 [many times]), perceived stigma (11 items), and internalized stigma (8 items). Perceived and internalized stigma items are rated 1 (strongly disagree) to 4 (strongly agree). Each subscale score is the mean of its items and ranges from 1 to 4. Higher scores indicate greater stigma. Change is calculated as the 3-month and 6- month score minus the baseline score. |
Baseline, 3 months, and 6 months
|
|
Change in observed HIV-related stigma in healthcare settings
Time Frame: Baseline, 3 months, and 6 months
|
Change in observed HIV-related stigma will be measured using 3 items assessing HIV-related stigma among health facility staff. Items ask how often participants observed stigmatizing behaviors in their health facility in the past 12 months (for example, health workers unwilling to care for a patient living with HIV). Each item is rated on a 4-point frequency scale: 1 (never), 2 (once or twice), 3 (several times), and 4 (most of the time). The score is the sum of the 3 items and ranges from 3 to 12. Higher scores indicate more observed stigma. |
Baseline, 3 months, and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Toan Ha, MD, DrPH, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY26010095
- R01TW013193 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data (IPD) underlying the results reported in publications will be deposited in an NIH-supported repository for HIV-related behavioral research. Access will be controlled and subject to a data use agreement prohibiting re-identification and unauthorized disclosure. Given the sensitive nature of HIV-related information and sexual orientation, and the risk of re-identification in small samples, data will be reviewed and de-identified before sharing. Data will be made available in accordance with repository policies and applicable consent, ethical, and institutional requirements, for as long as the repository maintains the data and makes them available.
IPD Sharing Time Frame
Data underlying published results will be available upon publication. Any other Aim 2 data will be shared by the end of the award period at the latest. Data will remain available in the repository for a minimum of 7 years.
IPD Sharing Access Criteria
Data will be available free of charge through the Mendeley Data repository. Users must register with the repository and agree to its terms, which restrict use to scientific research and aggregate statistical reporting. Data will be findable through a digital object identifier assigned by the repository. Access will follow the informed consent and institutional requirements, and any data designated as restricted use will be available under the repository's restricted-access terms.
IPD Sharing Supporting Information Type
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.